A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
Young Joo LeeHye Ryun KimMin Hee HongKi Hyeong LeeKeon Uk ParkGeon Kook LeeHyae Young KimSoo-Hyun LeeKun Young LimSung Jin YoonByoung Chul ChoJi-Youn HanPublished in: Cancer (2022)
A randomized Phase 2 study compared erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation. The erlotinib plus bevacizumab failed to improve median progression-free survival compared with the erlotinib alone. However, the progression-free survival benefit from erlotinib plus bevacizumab was found in patients with brain metastasis with no severe hemorrhagic adverse effects.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- free survival
- tyrosine kinase
- metastatic colorectal cancer
- small cell lung cancer
- open label
- randomized controlled trial
- early onset
- clinical trial
- white matter
- placebo controlled
- blood brain barrier
- functional connectivity
- subarachnoid hemorrhage
- cerebral ischemia